Compare PTON & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTON | TLX |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.2B |
| IPO Year | 2019 | N/A |
| Metric | PTON | TLX |
|---|---|---|
| Price | $5.06 | $10.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 4 |
| Target Price | $8.05 | ★ $21.13 |
| AVG Volume (30 Days) | ★ 14.3M | 231.9K |
| Earning Date | 05-07-2026 | 08-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.13 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.44 | N/A |
| P/E Ratio | ★ N/A | $150.33 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.65 | $6.28 |
| 52 Week High | $9.20 | $19.93 |
| Indicator | PTON | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 66.57 | 69.28 |
| Support Level | $4.09 | $10.60 |
| Resistance Level | $6.97 | $11.18 |
| Average True Range (ATR) | 0.33 | 0.33 |
| MACD | 0.08 | 0.08 |
| Stochastic Oscillator | 93.95 | 71.73 |
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product derives revenue from the portfolio of Connected Fitness Products and related accessories, as well as Precor-branded fitness products, delivery and installation services, Peloton Bike portfolio rental products, extended warranty agreements, branded apparel, and commercial service contracts. Subscription revenue is derived from monthly Subscription fees. The company generates maximum revenue from the Subscription segment. Geographically, the company derives a majority of its revenue from North America and the rest from International markets.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.